AMIX vs. VVOS, IRIX, NRXS, ALUR, QTI, PETV, SSKN, ICU, DHAI, and POAI
Should you be buying Autonomix Medical stock or one of its competitors? The main competitors of Autonomix Medical include Vivos Therapeutics (VVOS), IRIDEX (IRIX), NeurAxis (NRXS), Allurion Technologies (ALUR), QT Imaging (QTI), PetVivo (PETV), STRATA Skin Sciences (SSKN), SeaStar Medical (ICU), DIH Holding US (DHAI), and Predictive Oncology (POAI). These companies are all part of the "medical equipment" industry.
Autonomix Medical vs.
Vivos Therapeutics (NASDAQ:VVOS) and Autonomix Medical (NASDAQ:AMIX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.
Vivos Therapeutics has a beta of 7.31, indicating that its stock price is 631% more volatile than the S&P 500. Comparatively, Autonomix Medical has a beta of -3.08, indicating that its stock price is 408% less volatile than the S&P 500.
Vivos Therapeutics received 14 more outperform votes than Autonomix Medical when rated by MarketBeat users. However, 100.00% of users gave Autonomix Medical an outperform vote while only 57.69% of users gave Vivos Therapeutics an outperform vote.
Autonomix Medical has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -86.19%. Autonomix Medical's return on equity of -212.48% beat Vivos Therapeutics' return on equity.
In the previous week, Vivos Therapeutics had 3 more articles in the media than Autonomix Medical. MarketBeat recorded 6 mentions for Vivos Therapeutics and 3 mentions for Autonomix Medical. Vivos Therapeutics' average media sentiment score of 0.45 beat Autonomix Medical's score of 0.33 indicating that Vivos Therapeutics is being referred to more favorably in the media.
Vivos Therapeutics currently has a consensus price target of $6.30, suggesting a potential upside of 147.06%. Autonomix Medical has a consensus price target of $28.00, suggesting a potential upside of 1,602.13%. Given Autonomix Medical's higher possible upside, analysts clearly believe Autonomix Medical is more favorable than Vivos Therapeutics.
26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are held by institutional investors. 3.0% of Vivos Therapeutics shares are held by insiders. Comparatively, 32.4% of Autonomix Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Vivos Therapeutics has higher revenue and earnings than Autonomix Medical. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.
Summary
Vivos Therapeutics beats Autonomix Medical on 10 of the 16 factors compared between the two stocks.
Get Autonomix Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMIX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Autonomix Medical Competitors List
Related Companies and Tools
This page (NASDAQ:AMIX) was last updated on 4/4/2025 by MarketBeat.com Staff
Buy AMIX Stock Free AMIX Stock Alerts